<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-12T04:47:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/xsgcc434b7.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/xsgcc434b7.1</identifier>
                <datestamp>2025-06-06T15:16:17Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Zhou, Guo</dc:creator>
    <dc:title>Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>This dataset contains seven supplementary tables enabling assessment of the disease-modifying effects of early IL-17A inhibitor intervention on psoriasis in a real-world cohort. Table 1 presents baseline laboratory parameters stratified by disease duration:USDD: Psoriasis duration≤1 year，LDD1:Psoriasis duration&gt;1 year;SDD:Psoriasis duration≤2 year,LDD2:Psoriasis duration&gt;2 year. Tables 2-3 identify predictors of PASI 100 achievement at 4 and 52 weeks via logistic regression, demonstrating that shorter disease duration significantly increases the likelihood of achieving PASI 100 at both timepoints. Table 4 compares baseline characteristics and discontinuation rates by recurrence status, showing significantly longer mean disease duration and higher discontinuation rates in the recurrence group. Table 5 establishes predictors of relapse through logistic regression, revealing that each additional year of disease duration increases relapse risk by 3% (OR=1.03, 95%CI=1.007-1.054, p=0.01). Table 6 examines relapse after IL-17A discontinuation in ultra-short disease duration (USDD: Psoriasis duration≤1 year) versus long duration (LDD1:Psoriasis duration&gt;1 year): After adjusting for baseline PASI, BSA, and other confounders, USDD showed 78.8% lower relapse risk (OR=0.212, 95%CI=0.055-0.826, p=0.025). Table 7 compares short disease duration (SDD:Psoriasis duration≤2 year) versus long duration (LDD2:Psoriasis duration&gt;2 year): SDD was associated with 70.5% reduced relapse risk (OR=0.295, 95%CI=0.099-0.874, p=0.028) after similar adjustments.</dc:description>
    <dc:subject>Psoriasis</dc:subject>
    <dc:subject>Early Intervention</dc:subject>
    <dc:subject>IL-17A Signaling Pathway</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/xsgcc434b7.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/xsgcc434b7.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/xsgcc434b7</dc:relation>
    <dc:date>2025-06-06T15:16:17Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
